Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

Milestone achievement triggers $15 million payment from collaborator

GlaxoSmithKline

CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced the initiation of a pivotal Phase 3 clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes. As a result of the initiation of patient dosing in DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), Tolerx will receive a $15 million milestone payment from GlaxoSmithKline.

DEFEND is a randomized, placebo controlled Phase 3 trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers in North America and Europe. The trial will evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will reduce the amount of administered insulin required to control blood glucose levels by inhibiting the destruction of beta cells. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, and a reduction in long-term disease complications in established type 1 diabetics in the Diabetes Control and Complications Trial (DCCT).

"We are excited to have dosed the first patient in DEFEND and look forward to continued patient enrollment in this Phase 3 clinical trial. The initiation of DEFEND represents the culmination of a methodical, dose-ranging development plan, including the successful outcome from an end-of-Phase 2 meeting at FDA. We believe otelixizumab has the potential to provide an important new treatment option for patients with newly dia
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Mich., Aug. 6 Terumo Heart, Inc. announced,that ... Ventricular Assist,System (LVAS) took place on July 30 ... Arbor, Michigan. The surgery was performed by,Francis Pagani, ... Pivotal Trial. DuraHeart is the world,s first third,generation ...
... Nexgen Spine, a leading,developer of innovative spinal implants ... today that it has received CE mark,approval to ... European,Union., "We are delighted that the Physio-L(R) ... Alastair Clemow, Ph.D., President and CEO,of Nexgen Spine. ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/23/2013)... Onlinefitnessreview.com recently published a comprehensive review of ... makes this diet work and how it compares to ... components of the program: eliminating foods that may slow ... personal motivation that is needed to succeed; and, learning ... the metabolism rate in top gear. , Nutritionist ...
(Date:5/23/2013)... May 23 (HealthDay News) -- People who eat at ... realize -- and teens are the worst offenders, a ... calories in their meals by as much as 34 ... 23 percent, and adults by as much as 20 ... a news release from the Robert Wood Johnson Foundation, ...
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... beauticians may be affected by phthalates in these products, ... Mothers exposed to a common hairspray chemical while at ... with an abnormally placed urinary opening, a new report ... and nail and hair products contain chemicals called phthalates, ...
... BELLEVUE, Wash., Nov. 26 Edifecs, Inc., ... announced today that CNSI has,selected the Edifecs ... implementation of a new Medicaid Management Information ... Social Services (DSS). The Edifecs Healthcare,Accelerator ...
... research team led by Mitchell Lazar, MD, PhD, ... Metabolism at the University of Pennsylvania School of ... coordinates body rhythms and metabolism. , Lazar ... Penn Veterinary Medicine doctoral student Theresa Alenghat, studied ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... will present at the Piper Jaffray 20th Annual Health ... Wednesday, December 3, 2008. A simultaneous webcast of ...
... help regulate appetite , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... this year, a molecule produced in the small intestine will ... brain the impact of the fat you,ve just consumed. , ... a while. But, researchers are hoping that one day variations ...
... across the world are to share skills and experiences ... Africa, organised by the Wellcome Trust. , The conference ... will take place from 2-5 December at the Africa ... bring together practitioners working in the fields of public ...
Cached Medicine News:Health News:CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medicaid Program 2Health News:Molecular partnership controls daily rhythms, body metabolism 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 4Health News:Fat-Sensing Hormones Might Fight Obesity 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... active hormone synthesized within the follicular cells ... synthesized via a series of steps involving: ... (ii) iodination of tyrosine residues in the ... and 3,5-diiodotyrosine (MIT and DIT), and (iii) ...
... factor binding protein-3 (IGFBP-3) is the main binding ... as a component of the ~150 kDa ternary ... of IGF-I or IGF-II and ALS, allowing IGFBP-3, ... the IGFs. The molar concentration of IGFBP-3 in ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
Medicine Products: